People · Operator

Michael Voevodsky

Named in public records as an officer, director or promoter · active 2009–2020 · Biotechnology

2
Companies
8
Filings
$5.7M
Combined raised · real
Serial
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Salutaris Medical Devices IncBiotechnologySeed$5.4M$6.4M2009
MitoChem Therapeutics, Inc.BiotechnologyPre-Seed$236K$10.0M2020
Operator network

Michael Voevodsky at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Richard Love · 5 companies · 1 sharedRichard LoveWILLIAM LOMICKA · 4 companies · 1 sharedWILLIAM LOMICKAAkiteru Furukawa · 3 companies · 1 sharedAkiteru FurukawaEric Tooker · 3 companies · 1 sharedEric TookerGeorge Mimura · 2 companies · 1 sharedGeorge MimuraLaurence Marsteller · 1 companies · 1 sharedLaurence Marstell…Robert Selby · 1 companies · 1 sharedRobert SelbyRyan Lohrenz · 1 companies · 1 sharedRyan LohrenzWilliam Mumma · 1 companies · 1 sharedWilliam MummaBaerbel G. Rohrer · 1 companies · 1 sharedBaerbel G. RohrerGyda Caren Beeson · 1 companies · 1 sharedGyda Caren BeesonRick G. Schnellman · 1 companies · 1 sharedRick G. SchnellmanSalutaris Medical Devices Inc · $5.4M raisedSalutaris Medical Dev…MitoChem Therapeutics, Inc. · $0.2M raisedMitoChem Therapeutics…Michael VoevodskyMV
Michael Voevodsky Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Michael Voevodsky on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Richard Love15
WILLIAM LOMICKA14
Akiteru Furukawa13
Eric Tooker13
George Mimura12
Baerbel G. Rohrer11
Gyda Caren Beeson11
Ryan Lohrenz11
Laurence Marsteller11
William Mumma11
Robert Selby11
Rick G. Schnellman11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.